Full Press Release Details
MAINZ, Germany, Feb. 22, 2017 (GLOBE NEWSWIRE) -- BioNTech AG, a fully integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that Sean Marett, COO of BioNTech, will be presenting at Cowen and Company’s 37thAnnual Health Care Conference that is being held in Boston, MA from March 6 - 8, 2017. The presentation is scheduled for Tuesday, March 7 at 10:00 AM Eastern Standard Time.
Mr. Marett will provide an overview of the Company´s strategy and its most recent substantial progress, including an update of its clinical pipeline, an overview of its strategic collaborations, a summary of its two most recentNaturepublications related to its individualized mRNA cancer immunotherapeutics and the establishment of a GMP conform mRNA production facility at the Company´s headquarters in Germany.
About BioNTech AGBioNTech is Europe’s largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The company combines all building blocks for individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel checkpoint immunomodulators. BioNTech´s approach is validated by five top-tier corporate partnerships with Genentech, Genmab, Eli Lilly, Sanofi and Bayer Animal Health. Founded in 2008, BioNTech’s shareholders include the MIG Fonds, Salvia and the Strüngmann Family Office, with the Strüngmann Family Office as the majority shareholder. More information about BioNTech is available atwww.biontech.com.